MGMario Günscht

Mario Günscht

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mario Günscht has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Ali El-Armouche

    Institute of Pharmacology and Toxicology, Technische Universität Dresden, Dresden, Germany

    5 shared publications
  • Kaomei Guan

    Institute of Pharmacology and Toxicology, Technische Universität Dresden, 01307 Dresden, Germany

    3 shared publications
  • Rebecca Firneburg

    Institute of Pharmacology and Toxicology, Medical Faculty, TU Dresden, Dresden, Germany

    3 shared publications
  • Stephan R. Künzel

    Institut für Pharmakologie und Toxikologie, Technische Universität Dresden, Germany (E.C., M.G., M.S., M.S.S., J.S., F.D., C.B., S.Q., H.B., F.N., S.L., R.F., X.L., S.R.K., E.K., K.G., A.E.-A., M.W., S.K.).

    3 shared publications
  • Susanne Kammerer

    Medical Faculty, Institute of Pharmacology and Toxicology, Technische Universität Dresden, Dresden, Germany

    3 shared publications
  • Carolin Richter

    Institute of Pharmacology and Toxicology, Medical Faculty, TU Dresden, Dresden, Germany

    2 shared publications

Latest Publications

  • Open Access

    Differential regulation of cGMP pools during brown adipocyte differentiation

    by Mario Günscht, Sophie Fromknecht, Daniel Rowland, Alexander Pfeifer

    Obesity is characterized by an abnormal expansion in white adipose tissue (WAT) mass, which results in comorbidities such as, type 2 diabetes mellitus and cardiovascular disease. Brown adipose tissue (BAT), on the other hand, is distinguished by its ability to dissipate energy in the form of heat through a process called non-shivering thermogenesis, making it a promising target to combat obesity. Previous research has shown that cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) play a major role in BAT function. They enhance brownadipocyte(BA) differentiation, lipolysis, thermogenesis, mitochondrial biogenesis, energy expenditure and are able to induce browning of WAT. While the downstream effects of cGMP on BA differentiation have been investigated, the differences between the function and characteristics of local cGMP pools derived from either soluble guanylate cyclase (sGC) or particulate GCs (natriuretic peptide receptor A and B; NPRA and NPRB) remain unclear. BA were isolated from transgenic mice expressing the cytosolic cGMP FRET biosensor cGi-500 as well as BA obtained from human donor using the intensiometric green-cGull biosensor to probe the dynamics of cGMP production and degradation by the GCs and phosphodiesterases (PDEs) in real-time. Our results demonstrate that, depending on which GC produces cGMP, different subsets of PDEs are involved in its degradation, thereby locally confining the distinct cGMP pools. Furthermore, we show that during maturation in both human and murine BA, both the primary GC responsible for cGMP production as well as the distinct subsets of PDEs involved in its degradation change.

  • Open Access

    The cGMP-induced PDE2 stimulation as a novel antiarrhythmic strategy

    by Katharina Tergau, Moritz Gröner, Rebecca Firneburg, Eleder Cachorro, Mario Günscht, Kevser Kocas, Carolin Richter, Ali El-Armouche, Susanne Kämmerer

    Patients with myocardial infarction (MI) and heart failure (HF) often develop life-threatening arrhythmia. In the diseased heart, arrhythmia are forced by the imbalance between cyclic nucleotide pathways displaying a detrimental overactive cAMP- and a suppressed beneficial cGMP-signaling. Phosphodiesterase 2 (PDE2) is a keynode enzyme that connects both pathways via its unique property of cGMP-mediated activation to increase cAMP hydrolysis in cardiomyocytes (CM). PDE2 expression is upregulated in HF. Thus, the cGMP-induced PDE2 activation by either natriuretic peptides (NP) or vericiguat (VE) stimulating particulate or soluble guanylate cyclases might represent a new antiarrhythmic therapy. First, we demonstrated that the pharmacological inhibition or the CM-specific genetic deletion of PDE2 increased arrhythmia development after ischemia reperfusion injury in ex-vivo perfused mouse hearts. Importantly, the cGMP-mediated PDE2 stimulation with CNP or its approved drug analogue vosoritide (VO) reduced arrhythmia in WT hearts, while the PDE2 inhibitor BAY60-7550 prevent the observed antiarrhythmic effect. Second, we studied the underlying mechanisms on cellular level. In isolated CM, the β-adrenergic stimulation with isoprenaline (ISO) enhanced pro-arrhythmic triggers, like the I CaL, Ca 2+-sparks (CaSp) and -waves (SCW). Interestingly, the simultaneous incubation with CNP or VO significantly reduced the number of CaSp, SCW and I CaL amplitude. Of note, VE also decreased ISO-induced arrhythmogenic triggers in CM. Selective PDE2 inhibition or knockout clearly prevented the beneficial effects of cGMP-generating stimulators. Finally, we verified the antiarrhythmic effects of cGMP-induced PDE2 activation in CM and ex-vivo perfused hearts from diseased mice with HF, showing evidence for a novel therapeutic strategy.

  • Open Access

    The cGMP-induced PDE2 stimulation as a novel antiarrhythmic strategy

    by Katharina Tergau, Moritz Gröner, Rebecca Firneburg, Eleder Cachorro, Mario Günscht, Kevser Kocas, Carolin Richter, Ali El-Armouche, Susanne Kämmerer

  • Open Access

    CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2

    by Eleder Cachorro, Mario Günscht, Mario Schubert, Mirna S. Sadek, Johanna Siegert, Fabian Dutt, Carla Bauermeister, Susann Quickert, Henrik Berning, Felix Nowakowski, et al.

    Background: Ventricular arrhythmia and sudden cardiac death are the most common lethal complications after myocardial infarction. Antiarrhythmic pharmacotherapy remains a clinical challenge and novel concepts are highly desired. Here, we focus on the cardioprotective CNP (C-type natriuretic peptide) as a novel antiarrhythmic principle. We hypothesize that antiarrhythmic effects of CNP are mediated by PDE2 (phosphodiesterase 2), which has the unique property to be stimulated by cGMP to primarily hydrolyze cAMP. Thus, CNP might promote beneficial effects of PDE2-mediated negative crosstalk between cAMP and cGMP signaling pathways. Methods: To determine antiarrhythmic effects of cGMP-mediated PDE2 stimulation by CNP, we analyzed arrhythmic events and intracellular trigger mechanisms in mice in vivo, at organ level and in isolated cardiomyocytes as well as in human-induced pluripotent stem cell-derived cardiomyocytes. Results: In ex vivo perfused mouse hearts, CNP abrogated arrhythmia after ischemia/reperfusion injury. Upon high-dose catecholamine injections in mice, PDE2 inhibition prevented the antiarrhythmic effect of CNP. In mouse ventricular cardiomyocytes, CNP blunted the catecholamine-mediated increase in arrhythmogenic events as well as in I CaL , I NaL , and Ca 2+ spark frequency. Mechanistically, this was driven by reduced cellular cAMP levels and decreased phosphorylation of Ca 2+ handling proteins. Key experiments were confirmed in human iPSC-derived cardiomyocytes. Accordingly, the protective CNP effects were reversed by either specific pharmacological PDE2 inhibition or cardiomyocyte-specific PDE2 deletion. Conclusions: CNP shows strong PDE2-dependent antiarrhythmic effects. Consequently, the CNP-PDE2 axis represents a novel and attractive target for future antiarrhythmic strategies.


  • Open Access

    Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction

    by Erik Klapproth, Anke Witt, Pauline Klose, Johanna Wiedemann, Nikitha Vavilthota, Stephan R. Künzel, Susanne Kämmerer, Mario Günscht, David Sprott, Mathias Lesche, et al.

    After myocardial infarction the innate immune response is pivotal in clearing of tissue debris as well as scar formation, but exaggerated cytokine and chemokine secretion with subsequent leukocyte infiltration also leads to further tissue damage. Here, we address the value of targeting a previously unknown a disintegrin and metalloprotease 10 (ADAM10)/CX3CL1 axis in the regulation of neutrophil recruitment early after MI. We show that myocardial ADAM10 is distinctly upregulated in myocardial biopsies from patients with ischemia-driven cardiomyopathy. Intriguingly, upon MI in mice, pharmacological ADAM10 inhibition as well as genetic cardiomycyte-specific ADAM10 deletion improves survival with markedly enhanced heart function and reduced scar size. Mechanistically, abolished ADAM10-mediated CX3CL1 ectodomain shedding leads to diminished IL-1β-dependent inflammation, reduced neutrophil bone marrow egress as well as myocardial tissue infiltration. Thus, our data shows a conceptual insight into how acute MI induces chemotactic signaling via ectodomain shedding in cardiomyocytes.


  • Open Access

    Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation

    by Stephan R. Künzel, Maximilian Hoffmann, Silvio Weber, Karolina Künzel, Susanne Kämmerer, Mario Günscht, Erik Klapproth, Johanna S.E. Rausch, Mirna S. Sadek, Tomasz Kolanowski, et al.

    Rationale: Fibrosis promotes the maintenance of atrial fibrillation (AF), making it resistant to therapy. Improved understanding of the molecular mechanisms leading to atrial fibrosis will open new pathways toward effective antifibrotic therapies. Objective: This study aims to decipher the mechanistic interplay between PLK2 (polo-like kinase 2) and the profibrotic cytokine OPN (osteopontin) in the pathogenesis of atrial fibrosis and AF. Methods and Results: Atrial PLK2 mRNA expression was 10-fold higher in human fibroblasts than in cardiomyocytes. Compared with sinus rhythm, right atrial appendages and isolated right atrial fibroblasts from patients with AF showed downregulation of PLK2 mRNA and protein, along with increased PLK2 promotor methylation. Genetic deletion as well as pharmacological inhibition of PLK2 induced profibrotic phenotype conversion in cardiac fibroblasts and led to a striking de novo secretion of OPN. Accordingly, PLK2-deficient (PLK2 knockout) mice showed cardiac fibrosis and were prone to experimentally induced AF. In line with these findings, OPN plasma levels were significantly higher only in patients with AF with atrial low-voltage zones (surrogates of fibrosis) compared with sinus rhythm controls. Mechanistically, we identified ERK1/2 as the relevant downstream mediator of PLK2 leading to increased OPN expression. Finally, oral treatment with the clinically available drug mesalazine, known to inhibit ERK1/2, prevented cardiac OPN overexpression and reversed the pathological PLK2 knockout phenotype in PLK2 knockout mice. Conclusions: Abnormal PLK2/ERK1/2/OPN axis function critically contributes to AF-related atrial fibrosis, suggesting reinforcing PLK2 activity and/or OPN inhibition as innovative targets to prevent fibrosis progression in AF. Mesalazine derivatives may be used as lead compounds for the development of novel anti-AF agents targeting fibrosis.